Cargando…

Down regulation of Chk1 by p53 plays a role in synergistic induction of apoptosis by chemotherapeutics and inhibitors for Jak2 or BCR/ABL in hematopoietic cells

DNA-damaging chemotherapeutic agents activate apoptotic pathways in cancer cells. However, they also activate checkpoint mechanisms mainly involving Chk1 and p53 to arrest cell cycle progression, thus abbreviating their cytotoxic effects. We previously found that aberrant tyrosine kinases involved i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Umezawa, Yoshihiro, Kurosu, Tetsuya, Akiyama, Hiroki, Wu, Nang, Nogami, Ayako, Nagao, Toshikage, Miura, Osamu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5190110/ https://www.ncbi.nlm.nih.gov/pubmed/27286446 http://dx.doi.org/10.18632/oncotarget.9844

Ejemplares similares

Inhibition of the PI3K/Akt/GSK3 Pathway Downstream of BCR/ABL, Jak2-V617F, or FLT3-ITD Downregulates DNA Damage-Induced Chk1 Activation as Well as G2/M Arrest and Prominently Enhances Induction of Apoptosis
por: Kurosu, Tetsuya, et al.
Publicado: (2013)

PECAM-1 is involved in BCR/ABL signaling and may downregulate imatinib-induced apoptosis of Philadelphia chromosome-positive leukemia cells
por: WU, NAN, et al.
Publicado: (2012)

Proliferation and Survival Signaling from Both Jak2-V617F and Lyn Involving GSK3 and mTOR/p70S6K/4EBP1 in PVTL-1 Cell Line Newly Established from Acute Myeloid Leukemia Transformed from Polycythemia Vera
por: Nagao, Toshikage, et al.
Publicado: (2014)

Mechanisms for mTORC1 activation and synergistic induction of apoptosis by ruxolitinib and BH3 mimetics or autophagy inhibitors in JAK2-V617F-expressing leukemic cells including newly established PVTL-2
por: Ishida, Shinya, et al.
Publicado: (2018)

DNA Damage Stress and Inhibition of Jak2-V617F Cause Its Degradation and Synergistically Induce Apoptosis through Activation of GSK3β
por: Nagao, Toshikage, et al.
Publicado: (2011)

FLT3-ITD confers resistance to the PI3K/Akt pathway inhibitors by protecting the mTOR/4EBP1/Mcl-1 pathway through STAT5 activation in acute myeloid leukemia
por: Nogami, Ayako, et al.
Publicado: (2015)

Inhibition of USP9X Downregulates JAK2-V617F and Induces Apoptosis Synergistically with BH3 Mimetics Preferentially in Ruxolitinib-Persistent JAK2-V617F-Positive Leukemic Cells
por: Akiyama, Hiroki, et al.
Publicado: (2020)

Acceleration of Bcr-Abl(+) leukemia induced by deletion of JAK2
por: Grundschober, E, et al.
Publicado: (2014)

A novel MYD88 mutation, L265RPP, in Waldenström macroglobulinemia activates the NF-κB pathway to upregulate Bcl-xL expression and enhances cell survival
por: Nagao, T, et al.
Publicado: (2015)

Coexistence of JAK2 and BCR-ABL mutation in patient with myeloproliferative neoplasm
por: Hassan, Abdulaziz, et al.
Publicado: (2015)

A Small Molecule Inhibitor, OGP46, Is Effective against Imatinib-Resistant BCR-ABL Mutations via the BCR-ABL/JAK-STAT Pathway
por: Wei, Liuya, et al.
Publicado: (2020)

Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene
Publicado: (1995)

Inhibition of the STAT5/Pim Kinase Axis Enhances Cytotoxic Effects of Proteasome Inhibitors on FLT3-ITD–Positive AML Cells by Cooperatively Inhibiting the mTORC1/4EBP1/S6K/Mcl-1 Pathway()
por: Nogami, Ayako, et al.
Publicado: (2018)

FLT3-ITD Activates RSK1 to Enhance Proliferation and Survival of AML Cells by Activating mTORC1 and eIF4B Cooperatively with PIM or PI3K and by Inhibiting Bad and BIM
por: Watanabe, Daisuke, et al.
Publicado: (2019)

Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I
por: Mian, Afsar Ali, et al.
Publicado: (2012)

Thymoquinone Induces Downregulation of BCR-ABL/JAK/STAT Pathway and Apoptosis in K562 Leukemia Cells
por: Al-Rawashde, Futoon Abedrabbu, et al.
Publicado: (2021)

Induction of BCR‐ABL Fusion Genes by in vitro X‐irradiation
por: Ito, Takashi, et al.
Publicado: (1993)

Targeting BCR-ABL(+) stem/progenitor cells and BCR-ABL-T315I mutant cells by effective inhibition of the BCR-ABL-Tyr177-GRB2 complex
por: Chen, Min, et al.
Publicado: (2017)

Acute myeloid leukemia with t(3;21)(q26.2;q22) developing following low-dose methotrexate therapy for rheumatoid arthritis and expressing two AML1/MDS1/EVI1 fusion proteins: A case report
por: Tanaka, Keisuke, et al.
Publicado: (2017)

FLT3-ITD induces expression of Pim kinases through STAT5 to confer resistance to the PI3K/Akt pathway inhibitors on leukemic cells by enhancing the mTORC1/Mcl-1 pathway
por: Okada, Keigo, et al.
Publicado: (2017)

Allelic Expression Imbalance of JAK2 V617F Mutation in BCR-ABL Negative Myeloproliferative Neoplasms
por: Kim, Hye-Ran, et al.
Publicado: (2013)

SOX6 blocks the proliferation of BCR-ABL1(+) and JAK2V617F(+) leukemic cells
por: Barbarani, Gloria, et al.
Publicado: (2019)

JAK2阳性慢性髓性白血病合并疑似BCR-ABL变异型一例
Publicado: (2018)

BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene
por: Sharma, Nitesh, et al.
Publicado: (2015)

Pterostilbene downregulates BCR/ABL and induces apoptosis of T315I-mutated BCR/ABL-positive leukemic cells
por: Kawakami, Shohei, et al.
Publicado: (2022)

Emergence of BCR-ABL1 Chronic Myeloid Leukemia in a JAK2-V617F Polycythemia Vera
por: Lorenzo, Mariana, et al.
Publicado: (2020)

BCR: a new target in resistance mediated by BCR/ABL-315I?
por: Haberbosch, Isabella, et al.
Publicado: (2016)

The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins
por: You, Liangshun, et al.
Publicado: (2016)

Lymphoproliferative disorder risk after methotrexate treatment for rheumatoid arthritis
por: Tanaka, Keisuke, et al.
Publicado: (2023)

Expanding the Diversity of Allosteric Bcr-Abl Inhibitors
por: Deng, Xianming, et al.
Publicado: (2010)

An In-House Method for Molecular Monitoring of BCR-ABL
por: Sercan, Hakkı Ogün, et al.
Publicado: (2012)

Depression of oncogenecity by dephosphorylating and degrading BCR-ABL
por: Gao, Miao, et al.
Publicado: (2016)

Tyrosine kinase inhibitors induce alternative spliced BCR‐ABL (Ins35bp) variant via inhibition of RNA polymerase II on genomic BCR‐ABL
por: Yuda, Junichiro, et al.
Publicado: (2020)

AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells
por: Zhou, Liang L., et al.
Publicado: (2008)

The HSP90 inhibitor KW-2478 depletes the malignancy of BCR/ABL and overcomes the imatinib-resistance caused by BCR/ABL amplification
por: Zeng, Dachuan, et al.
Publicado: (2022)

Chimeric JAK2 Kinases Trigger Non-uniform Changes of Cellular Metabolism in BCR-ABL1-like Childhood ALL
por: Lukes, Julius, et al.
Publicado: (2023)

Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment
por: Oaxaca, Derrick M., et al.
Publicado: (2016)

Combined inhibition of BCR-ABL1 and the proteasome as a potential novel therapeutic approach in BCR-ABL positive acute lymphoblastic leukemia
por: Maletzke, Saskia, et al.
Publicado: (2022)

Prognostic factors influencing clinical outcome of allogeneic hematopoietic stem cell transplantation following imatinib-based therapy in BCR–ABL-positive ALL
por: Mizuta, S, et al.
Publicado: (2012)

Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1(T315I) and BCR-ABL1(T315I-E255K)
por: Mian, Afsar Ali, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_v0ptvqgbg7u3pqrkade99o5eme